Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase 2 Study of Cabazitaxel as Second-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer Previously Treated With Taxanes—A Hellenic Cooperative Oncology Group (HeCOG) TrialBr. J. Cancer 2020 Aug 01;123(3)355-361, A Koutras, F Zagouri, GA Koliou, E Psoma, I Chryssogonidis, G Lazaridis, D Tryfonopoulos, A Kotsakis, E Res, NK Kentepozidis, E Razis, A Psyrri, G Koumakis, HP Kalofonos, MA Dimopoulos, G Fountzilas
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.